- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.08. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage | 1.110 | GlobeNewswire (Europe) | Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance Appointment further... ► Artikel lesen | |
| 06.08. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 24.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies | 1 | GlobeNewswire (USA) | ||
| 15.07. | Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy | 1 | Benzinga.com | ||
| 15.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry | 280 | GlobeNewswire (Europe) | Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND ERNA-101 Plus Anti-PD-1 Achieved... ► Artikel lesen | |
| 14.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 | 1 | GlobeNewswire (USA) | ||
| 26.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients | 1 | GlobeNewswire (USA) | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.06. | Ernexa treibt Zelltherapie voran: Klinische Studie für dieses Jahr geplant | 3 | Investing.com Deutsch | ||
| 17.06. | Ernexa advances cell therapy toward clinical trial this year | 3 | Investing.com | ||
| 17.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study | 843 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| 09.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer | 2 | GlobeNewswire (USA) | ||
| 27.05. | Ernexa Therapeutics treibt IND-Antrag für Zelltherapie-Kandidaten ERNA-101 für Q3 voran | 1 | Investing.com Deutsch | ||
| 27.05. | Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing | 2 | Investing.com | ||
| 27.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development | 194 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| 20.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity | 1 | GlobeNewswire (USA) | ||
| 11.05. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 | 2 | GlobeNewswire (USA) | ||
| 06.05. | Ernexa-Aktie schießt nach Studienergebnissen zu Eierstockkrebs um 40 % in die Höhe | 10 | Investing.com Deutsch | ||
| 06.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | 367 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,400 | -3,23 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| TRAWS PHARMA | 0,550 | -0,02 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| CURIS | 1,230 | +5,78 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 3,490 | -0,29 % | Genprex Selects Andelyn Biosciences to Scale Manufacturing for Diabetes Gene Therapy Program | ||
| TVARDI THERAPEUTICS | 1,440 | -2,04 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| AINOS | 1,580 | 0,00 % | Ainos, Inc.: Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management | High-efficiency, on-site nitrogen generation is designed to protect high-value AI infrastructure, reduce oxidation and environmental degradation, and bring greater flexibility and resilience to semiconductor... ► Artikel lesen | |
| MATINAS BIOPHARMA | 0,179 | 0,00 % | Matinas BioPharma gets 2027 window to restore NYSE American listing compliance | ||
| ENVERIC BIOSCIENCES | 1,420 | +2,16 % | Morning Market Movers: Huachen AI Parking, FatPipe, Enveric Biosciences, Akanda See Big Swings | TEL AVIV (dpa-AFX) - At 8:00 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 3,770 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| SCINAI IMMUNOTHERAPEUTICS LTD | 1,900 | +2,15 % | Scinai Immunotherapeutics Ltd.: Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum | Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
| NIKI BIOSOLUTIONS | 6,230 | +0,48 % | Niki BioSolutions, Inc. - 8-K, Current Report | ||
| VIRAX BIOLABS GROUP | 2,605 | -0,95 % | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | ||
| ARTELO BIOSCIENCES | 5,970 | 0,00 % | Artelo Biosciences Announces Reverse Stock Split | SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling... ► Artikel lesen | |
| BIOCARDIA | 1,080 | 0,00 % | BCDA gives consortium first crack at water project | ||
| PASITHEA THERAPEUTICS | 0,585 | 0,00 % | Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial | -- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp.... ► Artikel lesen |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,150 (+3,48 %) liegt der Kurs bei 4,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.